FDA Approves Gilead’s Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
Event summary
- FDA approves Trodelvy for first-line treatment of metastatic triple-negative breast cancer (mTNBC) on June 24, 2026.
- Approval based on Phase 3 ASCENT-03 and ASCENT-04 trials showing significant progression-free survival benefits.
- Trodelvy can be used as monotherapy or in combination with Keytruda for PD-L1+ patients.
- NCCN recommends Trodelvy as a category 1 preferred first-line treatment option for mTNBC.
The big picture
This FDA approval positions Trodelvy as a frontline treatment for mTNBC, addressing a critical unmet need in oncology. The approval is based on robust clinical data demonstrating significant improvements in progression-free survival, potentially reshaping the treatment landscape for this aggressive form of breast cancer. Gilead's strategic focus on expanding Trodelvy's indications underscores its commitment to advancing cancer therapies.
What we're watching
- Market Penetration
- How quickly Gilead can capture market share in first-line mTNBC treatment.
- Combination Therapy
- Whether the combination of Trodelvy and Keytruda will become the new standard of care.
- Global Expansion
- The pace at which Gilead can secure regulatory approvals in other major markets.